Sugi Predict

Sugi Predict / Compounds / SCHEMBL6620534

SCHEMBL6620534

SCHEMBL6620534

O=C(O)C1CCC2(CCNCC2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.60
▸ GABRP O00591 1/20 0.60
▸ GABRD O14764 1/20 0.60
▸ GABRA1 P14867 1/20 0.60
▸ GABRB1 P18505 1/20 0.60
▸ GABRG2 P18507 1/20 0.60
▸ GABRB3 P28472 1/20 0.60
▸ GABRA5 P31644 1/20 0.60
▸ GABRA3 P34903 1/20 0.60
▸ GABRA2 P47869 1/20 0.60
▸ GABRB2 P47870 1/20 0.60
▸ GABRA4 P48169 1/20 0.60
▸ GABRE P78334 1/20 0.60
▸ PMP22 Q01453 1/20 0.60
▸ GABRA6 Q16445 1/20 0.60
▸ GABRG1 Q8N1C3 1/20 0.60
▸ GABRG3 Q99928 1/20 0.60
▸ GABRQ Q9UN88 1/20 0.60
▸ GRM2 Q14416 2/20 0.44
▸ GRM3 Q14832 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29849019 0.88 TSHR (0.50) TSHRGABRPGABRDGABRA1GABRB1
SCHEMBL1433252 0.88 TSHR (0.50) TSHRGABRPGABRDGABRA1GABRB1
SCHEMBL8004566 0.86 CYP2C19 (0.52) TSHRGABRPGABRDGABRA1GABRB1
SCHEMBL848416 0.84 CYP2C19 (0.50) TSHRGABRPGABRDGABRA1GABRB1
SCHEMBL22358969 0.81 KMT2A (0.44) TSHRGABRPGABRDGABRA1GABRB1
SCHEMBL12246933 0.81 CYP1A2 (0.39) TSHRGABRPGABRDGABRA1GABRB1
SCHEMBL31506988 0.80 TSHR (0.50) TSHRGABRPGABRDGABRA1GABRB1
SCHEMBL18394460 0.80 CYP2C19 (0.61) TSHRGABRPGABRDGABRA1GABRB1
SCHEMBL8810863 0.79 CYP2C19 (0.46) TSHRGABRPGABRDGABRA1GABRB1
SCHEMBL4532840 0.79 CYP2C19 (0.46) TSHRGABRPGABRDGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024017358-A1 MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 贝达药业股份有限公司 2024-01-25 — — WO claimed
CN-117917416-A KRAS G12D degradation agent and preparation method and application thereof 上海领泰生物医药科技有限公司 2024-04-23 — — CN disclosed
WO-2024017358-A1 MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 贝达药业股份有限公司 2024-01-25 — — WO disclosed
WO-2024015229-A1 PROTEASE/ENZYME CLEAVABLE LINKER-PAYLOADS AND PROTEIN CONJUGATES SUTRO BIOPHARMA, INC. (US) 2024-01-18 — — WO disclosed
WO-2024001839-A1 HETEROAROMATIC RING COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-01-04 — — WO disclosed
WO-2023217148-A1 AROMATIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF 杭州多域生物技术有限公司 2023-11-16 — — WO disclosed
EP-4192588-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2023-06-14 — — EP disclosed
WO-2013131010-A2 FUNCTION OF CHEMOKINE RECEPTOR CCR8 IN MELANOMA METASTASIS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2013-09-06 — — WO disclosed
WO-2012009217-A1 SPIROCYCLIC COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2012-01-19 — — WO disclosed
EP-0854869-B1 SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION LILLY CO ELI (US) 2004-08-25 — — EP disclosed
EP-1224186-B1 PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION MILLENNIUM PHARM INC (US) 2003-09-24 — — EP disclosed
US-20030055244-A1 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation MILLENNIUM PHARMACEUTICALS, INC. 2003-03-20 — — US disclosed
US-6528534-B2 Useful as glycoprotein IIb/IIIa antagonists for prophylaxis thrombosis, therapy of atheroschlerosis, arterioschlerosis, acute myocardial infarction, chronic stable angina, unstable angina, transient ischemic attacks and strokes MILLENNIUM PHARMACEUTICALS, INC. 2003-03-04 — — US disclosed
EP-1224186-A2 PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION COR THERAPEUTICS, INC. (US) 2002-07-24 — — EP disclosed
US-20020013325-A1 Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation FISHER MATTHEW J (US) 2002-01-31 — — US disclosed
US-6291469-B1 Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation ELI LILLY AND COMPANY 2001-09-18 — — US disclosed
WO-2001030780-A2 PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION COR THERAPEUTICS, INC. (US) 2001-05-03 — — WO disclosed
EP-0854869-A1 SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION ELI LILLY AND COMPANY (US) 1998-07-29 — — EP disclosed
WO-1997011940-A1 SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION ELI LILLY AND COMPANY (US) 1997-04-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055244-A1 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation PF4, PFKP, FGB TSHR 1147/4885GABRP 397/4885GABRD 1669/4885
US-20020013325-A1 Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation PF4, PFKP, SELP TSHR 2392/4885GABRP 369/4885GABRD 987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.